By using our website, you agree to our use of cookies.

Skip Navigation

Invest in Sana Biotechnology Inc on Stash

Sana Biotechnology, Inc is a preclinical-stage biotechnology company. The Company is focused on creating and delivering engineered cells as medicines for patients. The Company develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. The Company’s process of repairing and controlling genes in the body, referred to as gene therapy or in vivo cell engineering, requires in vivo delivery of a therapeutic payload and modification of the genome. The Company’s fusogen technology in preclinical studies targets cell surface receptors when combined with delivery vehicles to form fusosomes and allows cell-specific delivery across multiple different cell types. It focuses this technology on delivering payloads to T cells, hepatocytes, and hematopoietic stem cells (HSCs).

To buy fractional shares of Sana Biotechnology Inc stock, you'll need to sign up for Stash and open a personal portfolio.
Sana Biotechnology Inc

Ticker: SANA

Sana Biotechnology Inc

$5.18

+46.33%

(1W)
Nov ’25Dec ’25$4$5$6

$

SANA Performance Breakdown

Share Price

 

$5.18

Today's change

 

15.88%

Year to date change (YTD)

 

213.94%

Dividend yield

 

0.0

Last dividend paid

 

N/A

Last dividend pay date

 

N/A

About SANA

Sana Biotechnology, Inc is a preclinical-stage biotechnology company. The Company is focused on creating and delivering engineered cells as medicines for patients. The Company develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. The Company’s process of repairing and controlling genes in the body, referred to as gene therapy or in vivo cell engineering, requires in vivo delivery of a therapeutic payload and modification of the genome. The Company’s fusogen technology in preclinical studies targets cell surface receptors when combined with delivery vehicles to form fusosomes and allows cell-specific delivery across multiple different cell types. It focuses this technology on delivering payloads to T cells, hepatocytes, and hematopoietic stem cells (HSCs).

Sana Biotechnology Inc Stock Ticker

SANA

For more information

https://www.sana.com/

Certain companies are volatile

Certain companies can be volatile, meaning the stock price fluctuates significantly. Don’t put all your eggs into one basket and remember to keep the Stash Way in mind when you invest.

Sana Biotechnology Inc stock news

Why invest with Stash?

Fractional shares

Thousands of stocks and ETFs. No investing minimums.

Unlimited trades

Plus no add-on trading commission fees.

Diversification analysis

Custom investment recommendations can help you diversify.

Automatic investing

Dividend reinvestment,8 recurring investments, and more.

The Stock-Back® Card

We’ll give you matching stock in companies you shop at.1

Learn how to invest

Get professional advice and education at every step.

How to buy Sana Biotechnology Inc stock on Stash

Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.

Stash offers two subscription plans: Stash Growth and Stash+.

Once your market order of Sana Biotechnology Inc stock is complete, you'll officially be a shareholder of Sana Biotechnology Inc!

Invest in Sana Biotechnology Inc on Stash

Sana Biotechnology, Inc is a preclinical-stage biotechnology company. The Company is focused on creating and delivering engineered cells as medicines for patients. The Company develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. The Company’s process of repairing and controlling genes in the body, referred to as gene therapy or in vivo cell engineering, requires in vivo delivery of a therapeutic payload and modification of the genome. The Company’s fusogen technology in preclinical studies targets cell surface receptors when combined with delivery vehicles to form fusosomes and allows cell-specific delivery across multiple different cell types. It focuses this technology on delivering payloads to T cells, hepatocytes, and hematopoietic stem cells (HSCs).

To buy fractional shares of Sana Biotechnology Inc stock, you'll need to sign up for Stash and open a personal portfolio.